"Oh they certainly will when MSB reaches 'sustainable commercialisation'.
An authoritative-sounding term, which neatly fails to mention the risk vs reward analysis necessary in evaluation any biotech."
Only authoritative-sounding to those who fail to comprehend the concept, but for a great many investors, it represents a belts-and-braces approach to risk management.
On that important topic of managing risk, somewhat presciently, the phrase "self sustaining commercialisation" was first posted on these threads several years ago, ahead of the stock subsequently losing something like 90% of its value.
.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Type A Meeting with FDA
Ann: Mesoblast Type A Meeting with FDA, page-230
-
- There are more pages in this discussion • 345 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.324B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $5.890M | 5.014M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4990 | $1.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.06 | 18000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4990 | 1.225 |
3 | 8203 | 1.220 |
1 | 10643 | 1.215 |
1 | 184 | 1.205 |
3 | 101916 | 1.195 |
Price($) | Vol. | No. |
---|---|---|
1.060 | 18000 | 1 |
1.100 | 612 | 1 |
1.105 | 10536 | 2 |
1.130 | 25000 | 2 |
1.135 | 25224 | 1 |
Last trade - 15.59pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online